6 in 10 Austrialians in care take antidepressants … Pneumococcal shot could do double duty to fight viral respiratory infections … Study: Rebounds occurred with both COVID-19 antivirals … Quest stops...
Researchers pinpoint pre-diagnosis care paths in people with Alzheimer’s disease, other dementia
By
Kristen Fischer
Jan 26, 2024
Every person with Alzheimer’s disease and related dementias has a unique journey of how they discovered their diagnosis. A new study in Alzheimer’s & Dementia examined the patterns that led up...
Benefits of Alzheimer’s drug Leqembi persist when treatment is halted, trial shows
By
Alicia Lasek
Apr 09, 2023
A relative slowing of cognitive decline continues for up to two years in patients who stop taking the recently authorized drug, clinical trial data reveal.
Senators blast HHS’ restrictive coverage for Alzheimer’s drugs
By
Ron Rajecki
Mar 24, 2023
Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...
FDA denies request for expedited approval of Alzheimer’s drug
By
John Roszkowski
Jan 23, 2023
The Food and Drug Administration late last week denied Ely Lilly’s request for expedited approval of the Alzheimer’s drug donanemab, citing the need for more clinical trials to test the safety and...
Study seeks to shed light on COVID-19’s impact on the brain
By
John Roszkowski
Sep 23, 2022
A global consortium of researchers is seeking to uncover the short-term and long-term impacts of COVID-19 on the brain to assess whether it can lead to cognitive impairments later in life such as Alzheimer’s...